TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Genedrive ( (GB:GDR) ).
Genedrive plc has announced the successful results of a pilot program study on CYP2C19 genotype testing, presented at the UK Stroke Forum. The study supports the NHS’s implementation guide for using this testing to guide Clopidogrel prescriptions after ischemic stroke or TIA. The Genedrive® CYP2C19 ID Kit demonstrated a higher identification rate of patients unlikely to respond to Clopidogrel, impacting prescription practices positively. The test’s rapid results availability aligns with NHS goals, offering significant value by potentially saving bed days and healthcare professional hours, thus enhancing patient care and reducing costs.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercializes low-cost, rapid, and easy-to-use point-of-care pharmacogenetic platforms. These platforms help clinicians access critical genetic information quickly, aiding in personalized medicine choices for effective treatment, especially in emergency healthcare settings. The company has launched two flagship products: the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both designed to improve patient outcomes by personalizing treatment options.
Average Trading Volume: 57,428,098
Technical Sentiment Signal: Sell
Current Market Cap: £10.55M
See more data about GDR stock on TipRanks’ Stock Analysis page.